These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1337 related articles for article (PubMed ID: 16112192)

  • 21. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
    Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
    Clin Cancer Res; 2001 Dec; 7(12):3884-93. PubMed ID: 11751479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma.
    Munker R; Andreeff M
    Cytokines Mol Ther; 1996 Sep; 2(3):147-59. PubMed ID: 9384699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis.
    Ray S; Bullock G; Nuñez G; Tang C; Ibrado AM; Huang Y; Bhalla K
    Cell Growth Differ; 1996 Dec; 7(12):1617-23. PubMed ID: 8959329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia.
    van Stijn A; van der Pol MA; Kok A; Bontje PM; Roemen GM; Beelen RH; Ossenkoppele GJ; Schuurhuis GJ
    Haematologica; 2003 May; 88(5):497-508. PubMed ID: 12745269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of all-trans retinoic acid on chemotherapy induced apoptosis and down-regulation of Bcl-2 in human myeloid leukaemia CD34 positive cells.
    Ahmed N; Laverick L; Sammons J; Baumforth KR; Hassan HT
    Leuk Res; 1999 Aug; 23(8):741-9. PubMed ID: 10456672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effects of G-CSF, GM-CSF and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitors.
    Waga K; Furusawa S; Nagashima S; Saito K; Shishido H
    Int J Hematol; 1992 Aug; 56(1):17-27. PubMed ID: 1391803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytoprotective effects of hematopoietic growth factors on primary human acute myeloid leukemias are not mediated through changes in BCL-2, bax, or p21WAF1/CIP1.
    DiGiuseppe JA; Kastan MB; Weng LJ; Gore SD
    In Vivo; 1999; 13(1):1-6. PubMed ID: 10218124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia.
    Kim JS; Eom JI; Cheong JW; Choi AJ; Lee JK; Yang WI; Min YH
    Clin Cancer Res; 2007 Feb; 13(3):1019-28. PubMed ID: 17289898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells.
    Côme MG; Skladanowski A; Larsen AK; Laurent G
    Br J Cancer; 1999 Mar; 79(7-8):1090-7. PubMed ID: 10098741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells.
    Gu C; Ye T; Wells RA
    Leuk Res; 2006 Nov; 30(11):1447-51. PubMed ID: 16704876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Enhanced sensitivity to cytosine arabinoside by combined stimulation of steel factor and GM-CSF in a factor-dependent leukemic cell line, MO7e--in terms of a possible clinical application to AML treatment].
    Gotoh A; Kawanishi Y; Kurosawa K; Miyazawa K; Ohtaka M; Aizawa S; Kimura Y; Yoshikawa O; Toyama K
    Rinsho Ketsueki; 1993 Jul; 34(7):821-8. PubMed ID: 7689660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts.
    Cappellini A; Mantovani I; Tazzari PL; Grafone T; Martinelli G; Cocco L; Martelli AM
    Int J Mol Med; 2005 Dec; 16(6):1041-8. PubMed ID: 16273284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
    Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells.
    Kim YR; Eom JI; Kim SJ; Jeung HK; Cheong JW; Kim JS; Min YH
    J Pharmacol Exp Ther; 2010 Nov; 335(2):389-400. PubMed ID: 20699435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors.
    Hunter HM; Pallis M; Seedhouse CH; Grundy M; Gray C; Russell NH
    Br J Haematol; 2004 Oct; 127(1):26-33. PubMed ID: 15384974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
    te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
    Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
    Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
    Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
    Lin JM; Li B; Rimmer E; VanRoey M; Jooss K
    Exp Hematol; 2008 Mar; 36(3):319-28. PubMed ID: 18279719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.